Latest / Stock Movers / Munich Re Slides, Kingspan Slumps, Novo Nordisk Gains
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio news.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market, harnessing the power of Bloomberg Data.
- 0:16Speaker 1: Let's take a look at some of the stocks on
- 0:18Speaker 1: the move today here in Europe. I'm Caroline help get
- 0:20Speaker 1: alongside Lizzie Burden, and we're joined by Bloomberg's Markets Today
- 0:23Speaker 1: editor Sam Onstead. Good morning, Sam. So the German reinsurer
- 0:27Speaker 1: munich Re has dropped quite significantly.
- 0:29Speaker 3: Why yes, So the results overall, I think broadly met expectations.
- 0:34Speaker 3: But one thing that's come out of this is something
- 0:35Speaker 3: that's been mentioned quite a few times across this earning season,
- 0:38Speaker 3: which is the quality of the of the earnings. So overall,
- 0:42Speaker 3: the bottom line was boosted by things that are kind
- 0:44Speaker 3: of out of their control, specifically kind of slightly lower
- 0:46Speaker 3: natural catastrophe losses. So obviously they have, as all companies do,
- 0:50Speaker 3: no real control over how many natural catastrophes happen, and
- 0:53Speaker 3: so that has been mentioned a few times across different sectors.
- 0:56Speaker 3: That what investors are looking for is that the beats,
- 0:59Speaker 3: if they there is one, is coming from the core
- 1:01Speaker 3: operations of a company, and that communicary wasn't the case,
- 1:04Speaker 3: so a bit of a cut to their guidance and
- 1:06Speaker 3: means that the insurers are indeed a little bit weaker today.
- 1:09Speaker 1: Another one that's in the down on zone is Kingspan.
- 1:12Speaker 1: Just talk us through what the results said and remind
- 1:16Speaker 1: us what they do.
- 1:18Speaker 3: Sure's an Irish insulation company. So there are two sides
- 1:22Speaker 3: to the business. So there's the construction side of the
- 1:23Speaker 3: business and then there's another side of the business now
- 1:25Speaker 3: which is doing quite well in making money out of
- 1:27Speaker 3: data centers and providing in selection to data centers, but
- 1:29Speaker 3: the main part of the business is still construction. There's
- 1:32Speaker 3: been weakness there in the underlying markets in the US
- 1:34Speaker 3: and in Europe, so that has hit them a little bit.
- 1:37Speaker 3: And then with them as well, there's an interesting thing here.
- 1:39Speaker 3: So another big trend over only season there has been buybacks.
- 1:42Speaker 3: They have launched a new buyback program this morning, which
- 1:44Speaker 3: normally would give shares a bit of a boost. But
- 1:47Speaker 3: what analyst was saying this morning is that for Kingspan,
- 1:49Speaker 3: their strategy in the past has always been to use
- 1:51Speaker 3: their cash for acquisitions and to kind of keep building scale,
- 1:54Speaker 3: but now they seem to be shifting that and this
- 1:56Speaker 3: is a buyback program that's over eighteen to twenty four months.
- 2:00Speaker 3: They now appear to be using that cash for buybacks instead,
- 2:02Speaker 3: which gives a kind of different indication of both their
- 2:04Speaker 3: strategy and their view of the broader market.
- 2:07Speaker 1: Okay, so that on Kingspan. Meanwhile, again for Nova Nordisk shares,
- 2:13Speaker 1: which is also quite interesting given the pressures in that industry.
- 2:16Speaker 3: Yeah, I mean, they've had a pretty wild weekly q so,
- 2:20Speaker 3: you know, a big profit warning yesterday. They also were
- 2:25Speaker 3: very volatile in markets because of the results that came
- 2:29Speaker 3: out of Eli Lilly for their weight loss pill. They
- 2:31Speaker 3: were weaker than expected. That helped Novo Nordisks to rise
- 2:34Speaker 3: a little bit. You know, these are the two companies
- 2:36Speaker 3: that are really really competing with each other at the
- 2:38Speaker 3: top of that the weight loss industry globally. This morning,
- 2:42Speaker 3: intron Health, an analyst has upgraded their rating on Novo Nordisk,
- 2:47Speaker 3: saying that that now is likely to be the focus
- 2:49Speaker 3: this question of who is going to make the most
- 2:51Speaker 3: effective weight loss pill, and so they think that that overall,
- 2:55Speaker 3: because the focus is going to move there and the
- 2:57Speaker 3: results from Lily are a little bit weaker than Nova,
- 3:00Speaker 3: may well benefit.
- 3:00Speaker 2: From the stockmover's report from Bloomberg Radio. Check back with
- 3:05Speaker 2: us throughout the day for the latest roundup of companies
- 3:08Speaker 2: making news on Wall Street and for the latest market
- 3:11Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 3:16Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
- 3:19Speaker 2: the Bloomberg Business app.